Galmed Pharmaceuticals: CEO Letter to Shareholders Highlights Strong Cash Position, Scientific Advancements, and Growth Opportunities

Galmed Pharmaceuticals issued a Letter to Shareholders from CEO Allen Baharaff, highlighting the company's strong cash position, significant clinical advancements, and ambitious plans for the future. The company has $19.2 million in cash and no debt, and has expanded its therapeutic focus beyond liver disease with new data supporting development in oncology and cardiometabolic indications. Galmed is well-capitalized and positioned for growth opportunities, with a disciplined approach to R&D investment and a solid financial foundation.